Bristol-Myers Squibb Completes Divestment of Manufacturing Facility in Anagni, Italy
January 07 2020 - 3:00AM
Business Wire
Bristol-Myers Squibb Company (NYSE:BMY) announced today that it
has completed its previously announced divestment of its oral
solid, biologics, and sterile product manufacturing and packaging
facility in Anagni, Italy, to Catalent Inc.
The divestiture is part of Bristol-Myers Squibb’s strategy to
simplify and to realign its business portfolio to address changes
in its business and the future requirements of its evolving
pipeline.
The Anagni facility manufactures and packages cardiovascular,
anticancer, metabolic and anti-inflammatory medicines as well as
non-penicillin-based antibiotics, antivirals, analgesics as
injectables and biologics. The Company is focusing resources on its
highest priorities of discovering, developing and delivering
transformational medicines for patients facing serious
diseases.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information about Bristol-Myers Squibb, visit us
at BMS.com or follow us on LinkedIn, Twitter,
YouTube, Facebook, and Instagram.
Bristol-Myers Squibb Forward-Looking Statement
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of 1995
regarding, among other things, the research, development and
commercialization of pharmaceutical products and the transaction.
All statements that are not statements of historical facts are, or
may be deemed to be, forward-looking statements. Such
forward-looking statements are based on historical performance and
current expectations and projections about our future financial
results, goals, plans and objectives and involve inherent risks,
assumptions and uncertainties, including internal or external
factors that could delay, divert or change any of them in the next
several years, that are difficult to predict, may be beyond our
control and could cause our future financial results, goals, plans
and objectives to differ materially from those expressed in, or
implied by, the statements. These risks, assumptions, uncertainties
and other factors include, among others, any delay or inability of
Bristol-Myers Squibb to realize the expected benefits of the
transaction. No forward-looking statement can be guaranteed.
Forward-looking statements in this press release should be
evaluated together with the many risks and uncertainties that
affect Bristol-Myers Squibb’s business and market, particularly
those identified in the cautionary statement and risk factors
discussion in Bristol-Myers Squibb’s Annual Report on Form 10-K for
the year ended December 31, 2018, as updated by our subsequent
Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and
other filings with the Securities and Exchange Commission. The
forward-looking statements included in this document are made only
as of the date of this document and except as otherwise required by
applicable law, Bristol-Myers Squibb undertakes no obligation to
publicly update or revise any forward-looking statement, whether as
a result of new information, future events, changed circumstances
or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200107005282/en/
Media:media@bms.com609-252-3345
Investors:Tim Power, 609-252-7509,
timothy.power@bms.comNina Goworek, 908-673-9711,
ngoworek@celgene.com
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Sep 2023 to Sep 2024